C Difficile Infection

Vedolizumab, anti-TNF, and 5-ASA treatments were not linked to an increased risk of CDI, but investigators noted other baseline variables were significantly associated with CDI risk in patients with IBD.

Results from the study found a high risk of CDI associated with clindamycin and low risk associated with doxycycline and minocycline, also highlighting variation in CDI risk within and between classes of antibiotics.

A Mayo Clinic study shows FMT may provide benefit for patients experiencing recurrent infections during their C difficile treatment.

A protein targeted by some marketed lipid-lowering agents may increase risk of developing irritable bowel disease.

The first known dose-effect relationship study between colorectal neoplasia and smoking in patients with IBD strengthens the importance of achieving cessation.

New cohort analysis data provide more context into what factors influence the benefit of FMT in patients with recurrent CDI.

A study from China suggests calcium and magnesium malnutrition is associated with Crohn's disease inflammation and activity.

New data from the CONFIRM trial show the noninvasive FIT testing method is increasing in preference over colonoscopy by about 20% annually.

A cross-sectional analysis from China suggests approximately 1 in 10 individuals suffer from incontinence, though not all are seeking adequate care or specialist consultation.

Early-stage data support KAN-101, a liver-targeting drug that's vying to become the first treatment approved to treat celiac disease.

The reported C difficile healthcare-acquired infections rates per 10,000 patient days did not significantly change. The rates were 8.07 in the 6-month preintervention period and 8.77 in the intervention period for facilities A and B combined.

The area under the concentration-time curve (AUC) for vancomycin at discharge was the only modifiable factor found that was independently associated with patient safety outcomes.

The most frequent mutations found in the analyzed genomes was fluoroquinolone-associated mutations such as gyrA and there were 24 different sequence types were identified in the 130 isolates.

Kiwifruit supplementation did not have an impact on stool frequency or consistency, but magnesium oxide supplementation did result in improved stool frequency.

Experts discuss new and emerging treatments the management of CDI, highlighting the phase 3 trials for SER 109.

The median exposure of vedolizumab was 1.93 years and lower incidence rates were found for infliximab or adalimumab.

The interrupted time-series resulted in an increase in C. difficile infection incidences during the pre-pandemic period from 0.00 to 3.36 infections per 10,000 bed days during the COVID-19 pandemic.

RBX2660 showed similar efficacy and safety in treating patients with and without immunocompromised conditions.

Both the incidence and prevalence of inflammatory bowel disease is growing among the older population.

RBX2660 was the first ever live microbiota therapeutic to gain approval from the FDA for rCDI.

Joseph Reilly, BS, PharmD, BCGP, and Andrew Skinner, MD, discuss the potential benefits of using live-jslm early on to treat CDI, as well as the implications of this new treatment.

Joseph Reilly, BS, PharmD, BCGP, provides an overview of a new FDA-approved FMT therapy, live-jslm for the treatment of CDI.

Dr. Levine talks with Marketa Wills, MD, about the role of the payer in medicine.

For the maintenance trial, 42% and 55% of patients treated with upadacitinib 15 mg and 30 mg achieved clinical remission at week 52, compared to 14% of the placebo group.

Guselkumab is currently being evaluated as a treatment for both ulcerative colitis and Crohn's disease.

A redo surgery often improves the quality of life in a number of ways for patients with ulcerative colitis.

Pregnant women with celiac disease were not only at a higher risk of several pregnancy and delivery related complications, but also less likely to have a full-term uncomplicated delivery compared to the cohort without celiac disease.

In 2022, dupilumab became the first treatment approved by the US Food and Drug Administration for the treatment of patients with EoE.

The linaclotide group had significant improvements from baseline in the 12 week SBM frequency rate and 12-week stool consistency.

Candace Cotto, RN, and Andrew Skinner, MD, discuss the challenges of traditional fecal microbiota transplantation (FMT) in treatment of CDI.